Jesy Nelson has celebrated a significant victory in her campaign for the introduction of newborn screening for Spinal Muscular Atrophy (SMA) Type 1, following the announcement that the testing will now be rolled out across the entire United Kingdom. The singer, who has been a vocal advocate since her 14-month-old twins, Ocean and Story, were diagnosed with the rare muscle-wasting condition, shared her joy on social media.
Nelson stated that she received confirmation from the health minister and the Secretary of State for Health and Social Care that the screening would be implemented nationwide. She described the news as emotional and mind-blowing, expressing immense pride in everyone involved in achieving this goal. "This is all I ever wanted," Nelson said, emphasizing that the lives of future babies diagnosed with SMA will now be different.
The expansion of the screening program means hundreds of thousands of babies will be tested starting in October. This initiative aims to diagnose SMA early, a critical factor for improving outcomes for affected children. SMA can lead to progressive muscle weakness, affecting a child's ability to sit, crawl, or walk, and in severe cases, impacting breathing and swallowing. Early detection through a simple heel prick blood test allows for timely treatment.
Last month, a parliamentary debate resulted in a decision that only 72% of the country would have access to newborn screening, a outcome Nelson found deeply disappointing. She had previously expressed feeling "absolutely fuming" and "let down" by this partial rollout. However, the government has now confirmed the expansion to cover all of England.
Secretary of State for Health and Social Care, James Murray, acknowledged the tireless work of campaigners and stated that the expanded program ensures babies across England will be tested from birth, providing them with the best chance for a healthy life. He noted that the rollout is proceeding faster than initially planned, with labs set to begin testing in October 2026.
Giles Lomax, CEO of SMA UK, called the development a "hugely important step forward" after years of campaigning. He highlighted that when the newborn screening begins in October, thousands of babies will benefit from earlier diagnosis and life-changing treatment. Lomax also expressed gratitude to the entire SMA community, including families, clinicians, researchers, and supporters, for their contributions.
Spinal Muscular Atrophy is a genetic condition affecting motor neuron cells, leading to muscle wasting. Type 1 SMA is the most severe form, often diagnosed at birth, and can be fatal by age five if untreated. Other types vary in severity and age of onset.